Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. J. Seyfarth, S. Hammerschmidt, M. Halank, P. Neuhaus, H. Wirtz (Leipzig, Dresden, Germany). Everolimus improves exercise capacity and pulmonary vascular resistance in patients with advanced pulmonary hypertension – A pilot study. Eur Respir J 2011; 38: Suppl. 55, 2295

Member's Comments

No comment yet.

Related content which might interest you: Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 Effects of pulmonary rehabilitation in COPD patients with increased baseline arterial stiffness: The CIROCO study Source: Annual Congress 2010 - Pulmonary rehabilitation and chronic care: new developments in interventions, assessment and care Year: 2010 Pulmonary vascular response to exercise in heart-failure patients with pulmonary hypertension: role of a pre-capillary component Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Effects of pulmonary rehabilitation (PR) on arterial stiffness in patients with COPD: The CIROCO study Source: Annual Congress 2011 - Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation Year: 2011 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Pathophysiology of exercise limitation in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Screening for pulmonary vascular disease (PVD) in patients with portal hypertension by investigating pulmonary hemodynamics during exercise Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017